Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

1,364.70INR
6:28am EDT
Price Change (% chg)

Rs3.80 (+0.28%)
Prev Close
Rs1,360.90
Open
Rs1,380.00
Day's High
Rs1,394.40
Day's Low
Rs1,340.55
Volume
588,363
Avg. Vol
497,290
52-wk High
Rs1,442.15
52-wk Low
Rs832.70

LUPN.NS

Chart for LUPN.NS

About

Lupin Limited is a transnational pharmaceutical company. The Company produces a range of generic and branded formulations and bulk drugs. The Company along with its subsidiaries has manufacturing locations spread across India and Japan with trading and other incidental and related activities extending to world markets. The... (more)

Overall

Beta: 0.34
Market Cap (Mil.): Rs610,779.81
Shares Outstanding (Mil.): 448.81
Dividend: 3.00
Yield (%): 0.44

Financials

  LUPN.NS Industry Sector
P/E (TTM): 29.70 32.64 33.50
EPS (TTM): 45.82 -- --
ROI: -- 18.10 17.33
ROE: -- 18.80 18.19
Search Stocks

Merck KGaA agrees to market Lupin drugs in emerging countries

FRANKFURT - German drugmaker Merck KGaA said it struck a deal with Lupin Limited to market some of the Indian drugmaker's cardiovascular and diabetes treatments in emerging markets.

16 Sep 2014

Merck KGaA agrees to market Lupin drugs in emerging countries

FRANKFURT, Sept 16 - German drugmaker Merck KGaA said it struck a deal with Lupin Limited to market some of the Indian drugmaker's cardiovascular and diabetes treatments in emerging markets.

16 Sep 2014

CORRECTED-India's Lupin in deal to market U.S. firm Salix's drugs in Canada

(Corrects to say Salix will get upfront payment from Lupin in second paragraph)

12 Sep 2014

INDIA PRESS-Lupin targets 30 bln rupees India sales by year-end-Economic Times

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Aby Jose Koilparambil in Bangalore)

06 Aug 2014

UPDATE 1-Lupin expects India sales to grow 18-20 pct in fiscal 2015

* Q1 net profit up 56 pct at 6.25 bln rupees, beats estimates

30 Jul 2014

India's Lupin Q1 net up 56 pct on higher U.S. drug sales

MUMBAI, July 30 - Lupin Ltd, India's fourth-largest drugmaker by sales, reported a higher-than-expected profit in the first quarter, helped mainly by higher sales in the United States and India, and lower expenses.

30 Jul 2014

Exclusive - India's Lupin, U.S. firms weigh bids for GSK's mature drugs: sources

LONDON/MUMBAI - Indian generics firm Lupin , some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs being auctioned by GlaxoSmithKline (GSK) , five sources familiar with the matter said.

22 Jul 2014

INDIA PRESS-Lupin to exit from weaker brands, to buy stronger ones-Mint

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Aby Jose Koilparambil in Bangalore)

12 May 2014

Lupin pulls over 9,000 bottles of anti-infective Suprax from U.S. -FDA

MUMBAI, April 15 - India's Lupin Ltd is recalling 9,210 bottles of infection-preventing drug Suprax which failed a purity test in the United States, the U.S. Food and Drug Administration said.

15 Apr 2014

INDIA PRESS-Lupin approaches Cabinet Secretary to increase FII cap to 49 pct-Economic Times

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Abhiram Nandakumar in Bangalore)

02 Apr 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: SMC Global Securities Limited
$23.00
Provider: Kisan Ratilal Choksey Shares and Securities Private Limited
$58.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks